Co-Diagnostics, Inc.

NasdaqCM:CODX Stock Report

Market Cap: US$6.9m

Co-Diagnostics Management

Management criteria checks 4/4

Co-Diagnostics' CEO is Dwight Egan, appointed in Apr 2013, has a tenure of 13.42 years. total yearly compensation is $528.75K, comprised of 75.7% salary and 24.3% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $30.96K. The average tenure of the management team and the board of directors is 2.4 years and 7.2 years respectively.

Key information

Dwight Egan

Chief executive officer

US$528.8k

Total compensation

CEO salary percentage75.65%
CEO tenure13.4yrs
CEO ownership0.4%
Management average tenure2.4yrs
Board average tenure7.2yrs

Recent management updates

Recent updates

Narrative Update • Oct 18

Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access

Narrative Update on Co-Diagnostics Analysts have marginally increased their price target for Co-Diagnostics from $3.00 to $3.00, citing minimal changes in valuation inputs and updated financial forecasts as the rationale for this slight adjustment. What's in the News Announced development of a proprietary sample preparation instrument to streamline its point-of-care Co-Dx PCR Mycobacterium Tuberculosis Test.
Narrative Update • Oct 04

Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access

Analysts have significantly lowered their price target for Co-Diagnostics from $10.00 to $3.00, citing revised fair value estimates and a reduced expectation for future earnings multiples. What's in the News Co-Diagnostics completed a $3.85 million Follow-on Equity Offering, issuing 9,619,000 shares of common stock at $0.40 per share in a registered direct offering.
User avatar
New Narrative • May 04

Co-Dx PCR Platform And FDA 510(K) Clearance Will Expand Market Reach

Advancements in PCR platform and manufacturing enhance commercialization, potentially increasing revenues and profit margins through scale efficiencies.
Analysis Article • Feb 25

Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jun 14

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 18

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

One thing we could say about the covering analyst on Co-Diagnostics, Inc. ( NASDAQ:CODX ) - they aren't optimistic...

CEO Compensation Analysis

How has Dwight Egan's remuneration changed compared to Co-Diagnostics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$47m

Mar 31 2026n/an/a

-US$49m

Dec 31 2025US$529kUS$400k

-US$47m

Sep 30 2025n/an/a

-US$32m

Jun 30 2025n/an/a

-US$36m

Mar 31 2025n/an/a

-US$36m

Dec 31 2024US$717kUS$392k

-US$38m

Sep 30 2024n/an/a

-US$41m

Jun 30 2024n/an/a

-US$38m

Mar 31 2024n/an/a

-US$39m

Dec 31 2023US$1mUS$375k

-US$35m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$38m

Mar 31 2023n/an/a

-US$32m

Dec 31 2022US$2mUS$366k

-US$14m

Sep 30 2022n/an/a

US$15m

Jun 30 2022n/an/a

US$28m

Mar 31 2022n/an/a

US$40m

Dec 31 2021US$2mUS$350k

US$37m

Sep 30 2021n/an/a

US$42m

Jun 30 2021n/an/a

US$46m

Mar 31 2021n/an/a

US$51m

Dec 31 2020US$1mUS$309k

US$42m

Sep 30 2020n/an/a

US$28m

Jun 30 2020n/an/a

US$10m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$460kUS$275k

-US$6m

Compensation vs Market: Dwight's total compensation ($USD528.75K) is about average for companies of similar size in the US market ($USD653.62K).

Compensation vs Earnings: Dwight's compensation has been consistent with company performance over the past year.

CEO

Dwight Egan (73 yo)

13.4yrs
Tenure
US$528,750
Compensation

Mr. Dwight H. Egan serves as the Chairman and is its President at Co-Diagnostics, Inc. and has been its Director since April 2013 and serves as its Chief Executive Officer since April 2013. Mr. Egan has be...

Leadership Team

NamePositionTenureCompensationOwnership
Dwight Egan
Chairman13.4yrsUS$528.75k0.45%
$ 31.0k
Richard Abbott
President2.5yrsUS$360.00k0.37%
$ 25.7k
Dan Bohrer
Executive VP of Finance & Accounting and Principal Financial & Accounting Officer5yrsno datano data
David Nielsen
Chief Operating Officer2.4yrsno datano data
Christopher Thurston
Chief Technology Officer2.4yrsno datano data
Wesley Lindsey
Chief Scientific Officerless than a yearno datano data
Andrew Benson
Head of Investor Relationsno datano datano data
Mayuranki Almaula
Senior Vice President of Overseas Operations & Strategic Alliancesno datano datano data
Seth Egan
Chief Commercialization Officer & Strategy Officer2.4yrsno datano data
2.4yrs
Average Tenure
54yo
Average Age

Experienced Management: CODX's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dwight Egan
Chairman13.4yrsUS$528.75k0.45%
$ 31.0k
Richard Serbin
Independent Director9.3yrsUS$137.75k0.17%
$ 11.9k
Carl Wittwer
Chairman of Scientific Advisory Board4.5yrsno datano data
James Nelson
Independent Director7.1yrsUS$137.75k0.17%
$ 11.8k
Noriko Kusukawa
Member of Scientific Advisory Board4.5yrsno datano data
Edward Murphy
Independent Director7.3yrsUS$137.75k0.18%
$ 12.3k
Eugene Durenard
Independent Director7.3yrsUS$140.75k0.17%
$ 11.8k
Karen Carroll
Member of Scientific Advisory Board4.5yrsno datano data
7.2yrs
Average Tenure
67yo
Average Age

Experienced Board: CODX's board of directors are considered experienced (7.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 04:22
End of Day Share Price 2026/09/15 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Co-Diagnostics, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group
James SidotiSidoti & Company, LLC